Bovenden, Germany

Hansjorg Eibl

USPTO Granted Patents = 22 


Average Co-Inventor Count = 1.4

ph-index = 8

Forward Citations = 225(Granted Patents)


Location History:

  • Bovenden-Eddiegehausen, DE (1995)
  • Bovenden-Eddigehausen, DE (1997 - 1999)
  • Bovenden, DE (1976 - 2018)

Company Filing History:


Years Active: 1976-2018

Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents

Title: Innovations of Hansjorg Eibl: A Pioneer in Pharmaceutical Patents

Introduction

Hansjorg Eibl, based in Bovenden, Germany, is an accomplished inventor with a remarkable portfolio of 22 patents. His work primarily focuses on the development of innovative pharmaceutical agents and delivery systems that address critical health issues.

Latest Patents

Eibl's contributions to the field of pharmaceuticals are exemplified by his latest patents. One notable invention is the "Thermolabile liposome with a controlled release temperature." This invention details a thermolabile liposome that remains stable at 37°C in serum while controlling the release temperature between 40 and 80°C. This innovation is vital for enhancing drug delivery mechanisms and therapeutic efficacy.

Another significant patent is the "Process for the production of a pharmaceutical agent for oral or topical administration." This invention introduces a new pharmaceutical agent aimed at treating protozoal diseases, particularly leishmaniasis. The formulation involves active substances characterized by a general structure that includes hydrocarbon residues and various alkyl groups, enhancing its therapeutic properties.

Career Highlights

Hansjorg Eibl has made substantial contributions during his tenure at renowned organizations, including the Max Planck Society for the Advancement of Science and Ciba-Geigy Corporation. Through his experiences in these institutions, he has honed his expertise in pharmaceutical innovation and development, establishing himself as a key player in the field.

Collaborations

Throughout his career, Eibl has collaborated with notable peers, including Clemens Unger and Alfar Nicksch. These collaborations have likely fostered a rich exchange of ideas and knowledge, contributing to Eibl's success in the development of impactful inventions and research initiatives.

Conclusion

In conclusion, Hansjorg Eibl stands out as a prominent inventor in the pharmaceutical industry, with a strong portfolio of patents reflecting his innovative spirit and dedication to improving health outcomes. His latest inventions showcase his commitment to advancing drug delivery systems and treatments for diseases, making a lasting impact on the field of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…